HomeCompareIMBI vs JNJ

IMBI vs JNJ: Dividend Comparison 2026

IMBI yields 1818.18% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IMBI wins by $4103414683.81M in total portfolio value
10 years
IMBI
IMBI
● Live price
1818.18%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4103414683.84M
Annual income
$3,702,796,788,756,407.00
Full IMBI calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — IMBI vs JNJ

📍 IMBI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMBIJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMBI + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMBI pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMBI
Annual income on $10K today (after 15% tax)
$154,545.45/yr
After 10yr DRIP, annual income (after tax)
$3,147,377,270,442,946.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, IMBI beats the other by $3,147,377,270,438,960.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMBI + JNJ for your $10,000?

IMBI: 50%JNJ: 50%
100% JNJ50/50100% IMBI
Portfolio after 10yr
$2051707341.93M
Annual income
$1,851,398,394,380,548.20/yr
Blended yield
90.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

IMBI
Analyst Ratings
4
Buy
Consensus: Buy
Altman Z
-0.7
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMBI buys
0
JNJ buys
0
No recent congressional trades found for IMBI or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMBIJNJ
Forward yield1818.18%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$4103414683.84M$30.3K
Annual income after 10y$3,702,796,788,756,407.00$4,689.40
Total dividends collected$4074760433.31M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: IMBI vs JNJ ($10,000, DRIP)

YearIMBI PortfolioIMBI Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$192,518$181,818.18$10,592$272.30+$181.9KIMBI
2$3,477,331$3,271,336.99$11,289$357.73+$3.47MIMBI
3$58,943,217$55,222,471.89$12,123$472.89+$58.93MIMBI
4$937,891,469$874,822,227.57$13,141$629.86+$937.88MIMBI
5$14,012,869,532$13,009,325,660.38$14,408$846.81+$14012.86MIMBI
6$196,647,994,247$181,654,223,846.76$16,021$1,151.60+$196647.98MIMBI
7$2,592,865,386,485$2,382,452,032,641.56$18,122$1,588.22+$2592865.37MIMBI
8$32,132,661,421,271$29,358,295,457,731.54$20,930$2,228.20+$32132661.40MIMBI
9$374,409,247,740,494$340,027,300,019,734.44$24,792$3,191.91+$374409247.72MIMBI
10$4,103,414,683,838,736$3,702,796,788,756,407.00$30,274$4,689.40+$4103414683.81MIMBI

IMBI vs JNJ: Complete Analysis 2026

IMBIStock

iMedia Brands, Inc. operates as an interactive media company in the United States and internationally. It operates through three segments: Entertainment, Consumer Brands, and Media Commerce Services. The company operates television networks, including ShopHQ that offers jewelry and watches, home, beauty and health, and fashion and accessories; ShopBulldogTV, which provides male-oriented products and services; ShopHQHealth that offers women and men products and services focused on health and wellness categories, such as physical, mental and spiritual health, financial and motivational wellness, weight management, and telehealth medical services; ShopJewelryHQ for jewelry products and services; and 1-2-3.tv, a retailing marketplace for live and automated auctions. It also provides women's apparel and accessories under the Christopher & Banks brand; men and women accessories under the J.W. Hulme brand; and Shaq kitchen products and watches. In addition, the company operates online marketplaces for discounted merchandise through OurGalleria.com and TheCloseout.com; and Retail Media Exchange, an advertising auction platform for advertisers, digital publishers, and supply-side and demand-side platforms. Further, it offers a suite of value-added services; Float Left, an OTT software as a service app platform for media and consumer brands; and i3PL, an end-to-end, white label, managed services specializing in ecommerce customer experience and fulfillment services. The company was formerly known as EVINE Live Inc. and changed its name to iMedia Brands, Inc. in July 2019. iMedia Brands, Inc. was incorporated in 1990 and is headquartered in Eden Prairie, Minnesota.

Full IMBI Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this IMBI vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMBI vs SCHDIMBI vs JEPIIMBI vs OIMBI vs KOIMBI vs MAINIMBI vs ABBVIMBI vs MRKIMBI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.